Pharming Group reports first quarter 2026 financial results; on track for Joenja® U.S. pediatric label expansion and launches in Japan and Europe in 2026 Pharming Group to report first quarter 2026 financial results and provide business update on May 7 Pharming Group to participate in April investor conferences Pharming Group reports fourth quarter and full year 2025 financial results, delivering strong revenue growth and profitability with positive cash flow Pharming Group to report fourth quarter and full year 2025 financial results and provide business update on March 12 Pharming Group to present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference Pharming Group announces 2026 financial guidance and highlights rare disease pipeline at Investor Day Pharming Group receives Complete Response Letter from U.S. FDA for sNDA for Joenja® (leniolisib) in children aged 4 to 11 years with APDS Original-Research: Pharming Group NV (von First Berlin Equity Research GmbH): Buy Pharming Group reports preliminary 2025 revenues and announces Investor Day Pharming Group to participate in Oppenheimer Movers in Rare Disease Summit Pharming Group reports third quarter 2025 financial results with significant growth in revenue, profitability and cash flow Pharming Group to participate in Fireside Chat at Jefferies Global Healthcare Conference in London Pharming Group to report third quarter 2025 financial results and provide business update on November 6 Pharming Group announces U.S. FDA acceptance and Priority Review of supplemental New Drug Application for leniolisib in children with APDS aged 4 to 11 years